Palatin Technologies, Inc.
0KF3.L
London Stock Exchange13.40
USD
-0.20
- -
Palatin Technologies, Inc.
0KF3.L
(London Stock Exchange)
Recent
price
13.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Palatin Technologies, Inc. (Ticker: 0KF3.L) is a biopharmaceutical company that discovers and develops first-in-class medicines based on molecules modulating the melanocortin and natriuretic peptide receptor systems to address unmet medical needs in inflammatory, autoimmune, and other diseases. Founded in 1986 and headquartered in Cranbury, New Jersey, the company operates primarily in the United States with a strategic collaboration extending to Europe. Its lead commercialized product is Vyleesi (bremelanotide injection), an FDA-approved treatment for premenopausal women with generalized hypoactive sexual desire disorder (HSDD); the pipeline includes PL945 for obesity and metabolic diseases, Opalinotide for dry eye disease, PL8177 for inflammatory and autoimmune conditions, and an oral MC4R agonist PL7737 demonstrating positive preclinical efficacy in obesity models, alongside melanocortin receptor-targeted candidates for ocular and retinal diseases. In recent developments, Palatin Technologies closed an upsized $18.2 million public offering in November 2025 with full exercise of the underwriters' over-allotment option, strengthening its balance sheet to advance its obesity and inflammation pipelines toward clinical stages. The company entered a significant collaboration with Boehringer Ingelheim in August 2025 to develop first-in-class melanocortin receptor-targeted treatments for retinal diseases, earning a €5.5 million ($6.5 million) milestone payment in September 2025. Additional updates include a 1-for-50 reverse stock split in August 2025, presentations of promising preclinical data at ObesityWeek 2025 in November, and first quarter fiscal 2026 financial results highlighting pipeline progress and out-licensing advancements.